D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 119 Citations 65,666 1,156 World Ranking 1634 National Ranking 26

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Surgery

The scientist’s investigation covers issues in Hepatocellular carcinoma, Internal medicine, Carcinoma, Radiology and Sorafenib. His studies deal with areas such as Survival rate, Surgery, Pathology and Radiofrequency ablation as well as Hepatocellular carcinoma. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Placebo and Oncology.

His Carcinoma research incorporates themes from Lipiodol, Cancer research, Retrospective cohort study and Prospective cohort study. His Radiology study integrates concerns from other disciplines, such as Differential diagnosis and Pancreas. His work on Lenvatinib as part of general Sorafenib study is frequently linked to In patient, bridging the gap between disciplines.

His most cited work include:

  • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (1507 citations)
  • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial (1397 citations)
  • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (1199 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Hepatocellular carcinoma, Oncology, Radiology and Gastroenterology are his primary areas of study. Internal medicine is closely attributed to Placebo in his research. His Hepatocellular carcinoma research integrates issues from Carcinoma and Surgery.

He has researched Oncology in several fields, including Pembrolizumab, Cancer, Nivolumab and Regorafenib. His work on Radiofrequency ablation expands to the thematically related Radiology. The concepts of his Gastroenterology study are interwoven with issues in Hepatitis C and Hazard ratio.

He most often published in these fields:

  • Internal medicine (49.49%)
  • Hepatocellular carcinoma (48.89%)
  • Oncology (24.31%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (49.49%)
  • Hepatocellular carcinoma (48.89%)
  • Oncology (24.31%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Hepatocellular carcinoma, Oncology, In patient and Sorafenib. The various areas that Masatoshi Kudo examines in his Internal medicine study include Gastroenterology and Placebo. Masatoshi Kudo works mostly in the field of Hepatocellular carcinoma, limiting it down to topics relating to Pembrolizumab and, in certain cases, Cancer research.

His biological study deals with issues like Nivolumab, which deal with fields such as Ipilimumab. His In patient research spans across into fields like Stent and Radiology. His studies in Sorafenib integrate themes in fields like Regorafenib and Cohort study.

Between 2018 and 2021, his most popular works were:

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (529 citations)
  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (410 citations)
  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial (264 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Surgery

His scientific interests lie mostly in Hepatocellular carcinoma, Internal medicine, Oncology, Sorafenib and Lenvatinib. The Hepatocellular carcinoma study combines topics in areas such as Pembrolizumab, Clinical trial and Carcinoma. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.

His research on Oncology also deals with topics like

  • Systemic therapy which connect with Targeted therapy,
  • Phases of clinical research, which have a strong connection to Accelerated approval. His Sorafenib study which covers Hazard ratio that intersects with Subset Analysis and Liver cancer. His Lenvatinib research is multidisciplinary, incorporating elements of Liver function, Regorafenib and Multikinase inhibitor.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi.
The Lancet (2017)

1976 Citations

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito.
The Lancet (2017)

1881 Citations

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han.
The Lancet (2018)

1598 Citations

Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.

Michel Claudon;Christoph F. Dietrich;Byung Ihn Choi;David O. Cosgrove.
Ultrasound in Medicine and Biology (2013)

1186 Citations

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Masao Omata;Laurentius A. Lesmana;Ryosuke Tateishi;Pei Jer Chen.
Hepatology International (2010)

1094 Citations

Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

Masatoshi Kudo;Namiki Izumi;Norihiro Kokudo;Osamu Matsui.
Digestive Diseases (2011)

914 Citations

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Masao Omata;Ann Lii Cheng;Norihiro Kokudo;Masatoshi Kudo.
Hepatology International (2017)

836 Citations

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan.
Lancet Oncology (2018)

827 Citations

Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Masatoshi Kudo;Hobyung Chung;Yukio Osaki.
Journal of Gastroenterology (2003)

780 Citations

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson;Shukui Qin;Joong Won Park;Ronnie T.P. Poon.
Journal of Clinical Oncology (2013)

658 Citations

Editorial Boards

Liver Cancer
(Impact Factor: 12.43)

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Masatoshi Kudo

Jeong Min Lee

Jeong Min Lee

Seoul National University Hospital

Publications: 146

Josep M. Llovet

Josep M. Llovet

Icahn School of Medicine at Mount Sinai

Publications: 119

Christoph F. Dietrich

Christoph F. Dietrich

Hirslanden Private Hospital Group

Publications: 106

Kazuaki Chayama

Kazuaki Chayama

Hiroshima University

Publications: 96

Norihiro Kokudo

Norihiro Kokudo

University of Tokyo

Publications: 92

Joon Koo Han

Joon Koo Han

Seoul National University Hospital

Publications: 89

Jordi Bruix

Jordi Bruix

University of Barcelona

Publications: 89

Fabio Piscaglia

Fabio Piscaglia

University of Bologna

Publications: 88

Jia Fan

Jia Fan

Fudan University

Publications: 83

Timothy M. Pawlik

Timothy M. Pawlik

The Ohio State University Wexner Medical Center

Publications: 75

Kwang Hyub Han

Kwang Hyub Han

Yonsei University

Publications: 74

Osamu Yokosuka

Osamu Yokosuka

Chiba University

Publications: 73

Namiki Izumi

Namiki Izumi

Musashino Red Cross Hospital

Publications: 71

Kiyoshi Hasegawa

Kiyoshi Hasegawa

University of Tokyo

Publications: 69

Wan Yee Lau

Wan Yee Lau

Chinese University of Hong Kong

Publications: 68

Valérie Vilgrain

Valérie Vilgrain

Université Paris Cité

Publications: 65

Trending Scientists

Yuming Fang

Yuming Fang

Jiangxi University of Finance and Economics

Gerrit E. W. Bauer

Gerrit E. W. Bauer

Tohoku University

Jin Kon Kim

Jin Kon Kim

Pohang University of Science and Technology

Elizabeth M. J. Gillam

Elizabeth M. J. Gillam

University of Queensland

Matthew C. Wolfgang

Matthew C. Wolfgang

University of North Carolina at Chapel Hill

Monique Gillis

Monique Gillis

Ghent University

Katsutoshi Arai

Katsutoshi Arai

Hokkaido University

Pietro Liò

Pietro Liò

University of Cambridge

Gerhard Kuhn

Gerhard Kuhn

Alfred Wegener Institute for Polar and Marine Research

Robert Mikutta

Robert Mikutta

Martin Luther University Halle-Wittenberg

Gregory W. McCarty

Gregory W. McCarty

Agricultural Research Service

Alexander Luria

Alexander Luria

Lomonosov Moscow State University

James A. Ashton-Miller

James A. Ashton-Miller

University of Michigan–Ann Arbor

Andrew J. Powell

Andrew J. Powell

Boston Children's Hospital

Anthony P. Adamis

Anthony P. Adamis

Genentech

Something went wrong. Please try again later.